The transplant community is divided regarding whether substitution with generic immunosuppressants is appropriate for organ transplant recipients. We estimated the and brand-name tacrolimus or mycophenolate mofetil were calculated over time by transplanted organ and drug. Among Part D kidney, liver, and heart beneficiaries, the proportion dispensed generic tacrolimus reached 50%-56% at 1 year after first generic approval and 78%-81% by December 2013. The proportion dispensed generic mycophenolate mofetil reached 70%-73% at 1 year after generic market entry and 88%-90% by December 2013. There was wide interstate variability in generic uptake, with faster uptake in Colorado compared with most other states. Overall, generic substitution for tacrolimus and mycophenolate mofetil for organ transplant recipients increased rapidly following first availability, and utilization of generic immunosuppressants exceeded that of brand-name products within a year of market entry.
| INTRODUC TI ON
To reduce the risk of graft rejection and loss after organ transplantation, transplant recipients must have access to immunosuppressive medications (ISMs). ISM costs can be a substantial burden for transplant patients, potentially limiting access and increasing nonadherence.
1,2 The use of therapeutically equivalent generic products can reduce recipients' and payers' financial burdens. However, the transplant community has expressed concerns about generic substitution for brand-name ISMs and the substitution of one generic product for another. [2] [3] [4] [5] [6] [7] In addition, patients may not believe generic
ISMs are equivalent to their brand-name counterparts and may not be receptive to payer-driven generic substitution. 2, 8 Previous generic vs brand-name ISM comparison studies are limited by small sample sizes, retrospective designs, inclusion of only healthy volunteers, or inconsistent results across studies. 6, [9] [10] [11] [12] [13] Results from bioequivalence studies and expected cost savings associated with generic ISMs have led several US and international professional transplant societies to issue guidelines advocating for generic ISM substitution. 3, 14, 15 If all prescription requirements are met, generic substitution can even be carried out without prescriber or patient input in some states. 6, [16] [17] [18] Generic-for-brand or generic-for-generic substitutions can also confuse patients.
Different versions of a drug can have different appearances, which may lead to increased risk of medication errors and nonadherence. 6 Partly due to these concerns, the aforementioned guidelines all recommend that generic substitution of ISMs only be implemented with frequent patient monitoring, patient education on differences between products, and caution under certain clinical conditions.
The most widely used ISMs by US organ transplant recipients are tacrolimus (TAC) and mycophenolate mofetil (MMF). 19 The first generic versions of MMF and TAC were approved by the US Food 
| MATERIAL S AND ME THODS

| Study design and data sources
| Study sample
Patients were eligible for primary analyses if they (1) recipients, and additionally return to dialysis for kidney recipients.
| Outcome variables
Our primary outcome was brand-name or generic PDEs or pharmacy claims for TAC and MMF. As our focus was uptake of generic ISMs among transplant recipients, we did not assess conversions from generic to brand or between different types of generic ISM products.
Mycophenolate sodium is used as an alternative to MMF in some transplant recipients; however, MPS was not included in the main analysis because the first MPS generic application was approved by the FDA late in our study period (2012). were excluded from analysis for that month due to imprecision of percentage estimates. We did not perform this analysis for heart recipients because half or more states had less than 20 patients during most calendar months.
| Independent variables
To evaluate whether yearly state-level uptake of generic ISM was associated with differences in state laws governing generic substitution, we used linear generalized estimating equation models with sandwich-type standard error estimators to account for correlations among years within states, adjusting for calendar year. States with less than 20 patients in a year were excluded from that year's analyses.
All analyses were conducted using SAS version 9.4 (SAS Institute, Inc., Cary, NC).
| RE SULTS
There were 26 070 kidney, 15 548 liver, and 6685 heart transplant recipients enrolled in Part D who met study eligibility criteria (Figure 1 ), accounting for 7.6%, 13.5%, and 11.8% of all kidney, liver, and heart transplant recipients since 1987, respectively. These recipients were mostly male, white, aged 50-64 years (Table 1) Among Part D beneficiaries with PDEs for TAC (generic or brand name), the proportion of kidney, liver, and heart recipients with
PDEs for generic TAC reached 56%, 50%, and 51%, respectively, at 1 year after approval of the first generic TAC product ( Figure 2 ).
In contrast, generic MMF was unavailable until 9 months after the approval date of the first generic product. However, after 1 year of entering the market, the proportion dispensed generic MMFs (out of all MMF PDEs) increased to 73%, 70%, and 71% for kidney, liver, and heart recipients, respectively. By December 2013, across organs, 78-81% and 88-90% of recipients with PDEs for TAC and MMF were dispensed the generic products, respectively. For both ISM types, adoption patterns for generic products were similar across organ type.
In the CO-APCD, 74% and 78% of kidney and liver recipients were dispensed generic TAC at 1 year after first generic approval, respectively; and 80% of kidney recipients were dispensed generic MMF at 1 year after first generic market entry. By December 2013, 90% and 89% of kidney and liver recipients were dispensed generic TAC, respectively; and 95% of kidney recipients were dispensed generic MMF.
Results from sensitivity analyses showed that brand-name ISM prescriptions were more likely to have dispense as written (DAW) codes that precluded generic substitution, including prescriber and patient preferences, while other factors did not appear to affect generic uptake (Supplement III). ual. 22 This difference may reflect some practitioners' initial hesitancy to allow patients to switch to generic TAC given that TAC is a narrow therapeutic index (NTI) medication, 2,23 whereas MMF is not.
| D ISCUSS I ON
NTI status implies greater risk of adverse clinical consequences from too high or too low drug concentrations. 2, 7, 17, 24 Thus, until therapeutic equivalency is confirmed in clinical practice, there may be more apprehension about the efficacy of generic versions of NTI medications such as TAC.
2,25
Our study found that uptake of generic ISMs was largely influenced by generic market entry and calendar time. Adoption of generic ISMs did not appear to depend on time elapsed since transplant. The uptake patterns for each generic ISM was consistent across types of transplanted organs.
Additionally, market forces may have influenced the uptake of generic ISMs. For example, by adding the generic product to its formulary with lower patient copayments, payers may incentivize generic ISM use. 22 Pharmaceutical industry practices such as patient copay assistance programs (data unavailable) may also influence generic uptake. 26, 27 Furthermore, prescriber practices and patient preferences appear to have affected brand-name vs generic prescriptions substantially, as observed from our sensitivity analysis of DAW status of PDEs for brand-name ISMs. Generic substitution at the pharmacy is not mandatory in all states; 18 thus it is possible that pharmacy practices (unavailable in our data) may also affect selection of generic products.
Introduction of generic drug products is expected to reduce costs for payers and patients, potentially increasing access and adherence. Assessment of these benefits in transplantation necessitates exploration of the longitudinal use of generic ISMs, which has not previously been reported. As more transplant recipients use generic ISMs, the potential cost savings to both payers and patients may increase. Since ISM costs paid by patients may exceed $500/ month 7 and overall ISM costs may exceed $4000/month, 2 the magnitude of the potential cost savings could be substantial. 
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